Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy

Medical Oncology

Volumn 28, Issue 3, 2011, Pages 835-839

  Liu, Li ^a   Chen, Renan ^a   Huang, Siyong ^a   Wu, Yanlan ^a   Li, Guohui ^a   Liu, Qiang ^a   Yin, Dandan ^a   Liang, Yingmin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Imatinib; Leukemia stem cell; siRNA; SOD1

Indexed keywords

ACETYLCYSTEINE; CD34 ANTIGEN; COPPER ZINC SUPEROXIDE DISMUTASE; IMATINIB; REACTIVE OXYGEN METABOLITE;

ARTICLE; CANCER GROWTH; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIZATION; GENE INACTIVATION; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL SEPARATION; CELL SURVIVAL; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PIPERAZINES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE; TRANSFECTION;

EID: 80052490883     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9529-9     Document Type: Article

References (16)

1. Y Ben-Neriah GQ Daley AM Mes-Masson ON Witte D Baltimore 1986 The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene Science 233 4760 212 214 3460176 10.1126/science.3460176 1:CAS:528:DyaL28XkvFagtrs%3D
2. BJ Druker S Tamura E Buchdunger S Ohno GM Segal S Fanning J Zimmermann NB Lydon 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 5 561 566 8616716 10.1038/nm0596-561 1:CAS:528:DyaK28Xislyhs70%3D
3. A McGahon, et al. 1994 BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death Blood 83 5 1179 1187 8118022 1:CAS:528:DyaK2cXivFGgt74%3D
4. DJ Deangelo EC Attar 2010 Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice Leuk Lymphoma 51 3 363 375 20038231 10.3109/10428190903518295 1:CAS:528:DC%2BC3cXitVOmsL4%3D
5. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematol Am Soc Hematol Educ Prog. 2009:477-487.
6. M Breccia G Alimena 2009 Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL Curr Drug Targets 10 6 530 536 19519355 10.2174/138945009788488468 1:CAS:528:DC%2BD1MXoslCjur0%3D
7. E Weisberg PW Manley SW Cowan-Jacob A Hochhaus JD Griffin 2007 Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia Nat Rev Cancer 7 5 345 356 17457302 10.1038/nrc2126 1:CAS:528:DC%2BD2sXksFSiu7o%3D
8. A Gontarewicz, et al. 2008 PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases Leuk Res 32 12 1857 1865 18514829 10.1016/j.leukres.2008.04.012 1:CAS:528:DC%2BD1cXhtFekt7vP
9. F Belloc, et al. 2009 The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells Leukemia 23 4 679 685 19158834 10.1038/leu.2008.364 1:CAS:528:DC%2BD1MXks1SitL0%3D
10. H Konig, et al. 2008 Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors Leukemia 22 4 748 755 18273048 10.1038/sj.leu.2405086 1:CAS:528:DC%2BD1cXks12rtL8%3D
11. Z Tothova, et al. 2007 FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress Cell 128 2 325 339 17254970 10.1016/j.cell.2007.01.003 1:CAS:528:DC%2BD2sXhsVOqsr0%3D
12. K Naka, et al. 2010 TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia Nature 463 7281 676 680 20130650 10.1038/nature08734 1:CAS:528:DC%2BC3cXhsVygtL4%3D
13. S Ghaffari 2008 Oxidative stress in the regulation of normal and neoplastic hematopoiesis Antioxid Redox Signal 10 11 1923 1940 18707226 10.1089/ars.2008.2142 1:CAS:528:DC%2BD1cXhtVymsbrF
14. K Naka T Muraguchi T Hoshii A Hirao 2008 Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells Antioxid Redox Signal 10 11 1883 1894 18627347 10.1089/ars.2008.2114 1:CAS:528:DC%2BD1cXhtVymsbvP
15. CK Bruns RR Kopito 2007 Impaired post-translational folding of familial ALS-linked Cu, Zn superoxide dismutase mutants EMBO J 26 3 855 866 17255946 10.1038/sj.emboj.7601528 1:CAS:528:DC%2BD2sXhtlOkt70%3D
16. Y Furukawa TV O'Halloran 2006 Posttranslational modifications in Cu, Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis Antioxid Redox Signal 8 5-6 847 867 16771675 10.1089/ars.2006.8.847 1:CAS:528:DC%2BD28XlsFOnu7s%3D